BioTech guy. Ex-BigPharma. Father, husband, sailboat racer & guitar aficionado. Tweets are mine.
Cambridge, MA
Joined March 2015
- Tweets850
- Following530
- Followers1.9K
- Likes3.3K
Don Nicholson retweeted
Today we reached another exciting clinical milestone, announcing positive data from a Phase Ib/IIa #cardiovascular (CV) risk study of lead #NLRP3 #inflammasone inhibitor candidate, NT-0796.
For more: nodthera.com/news/nodtheras-…
#Neuroinflammation #DrugDiscovery #obesity
Don Nicholson retweeted
We are pleased to announce that the first patients have been dosed in a Phase Ib/IIa #cardiovascular risk study to assess the impact of NT-0796 on cardio-metabolic biomarkers and #neuroinflammation.
For more: nodthera.com/news/nodthera-a…
#NLRP3
Don Nicholson retweeted
On Thursday, Joanne Kotz, Ph.D., Co-Founder & CEO, and Doug Pagan, CFO and COO, kick off Jnana’s fall investor conference calendar during a fireside chat at 1:50 p.m. at @Citi’s 18th Annual BioPharma Conference. ow.ly/f5XB50PIgIX #drugdiscovery #biotechnology
Don Nicholson retweeted
NodThera Looks To Compete In Long-Awaited Inflammasome Field With Parkinson’s Therapy
bit.ly/42PtOTv #PharmaScrip
Don Nicholson retweeted
We are thrilled to be working with fantastic colleagues at Roche to leverage our RAPID platform to advance programs targeting challenging-to-drug targets, including this immune protein-protein interaction.
jnanatx.com/jnana-therapeuti…
Don Nicholson retweeted
Moderna and @generationbio announced today that the two companies have entered into a strategic collaboration to combine Moderna’s biological and technical expertise with core technologies of Generation Bio’s non-viral #genetic medicine platform. The collaboration aims to expand the application of each company’s platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic #medicines.
Read more: investors.modernatx.com/news…
Don Nicholson retweeted
We are delighted to announce a $62.5 million financing, led by @BainCapital. This investment adds to our financial strength during an exciting year for Disc as we look towards multiple data readouts and trial initiations across our #hematology portfolio. globenewswire.com/news-relea…
Don Nicholson retweeted
Disc is excited to announce a licensing agreement with Mabwell Therapeutics for novel investigational anti-#TMPRSS6 antibodies, including phase 1-ready MWTX-003, which will expand our portfolio of programs to control #iron homeostasis!
Read more here: globenewswire.com/news-relea…
Don Nicholson retweeted
Today we announced Disc has completed its merger with Gemini Therapeutics. The combined company, advancing Disc’s pipeline of hematology programs, will commence trading under the ticker symbol $IRON
Read more: globenewswire.com/news-relea…
Don Nicholson retweeted
Jnana is thrilled to announce a $107M Series C financing and initiation of our Phase 1 clinical trial in #PKU. The financing will support the PKU program and our preclinical programs in immune-mediated diseases and cancer. Learn more: bit.ly/3UYTiuc #BiotechNews
Don Nicholson retweeted
Today we’re proud to announce our second collaboration with @Roche to apply our next generation chemoproteomics platform, RAPID, to address challenging-to-drug targets in multiple target classes. Learn more here: bit.ly/3AeRepG
#Biotech
Don Nicholson retweeted
@muna_tx has been #awarded a $4.9m grant from @MichaelJFoxOrg to support ongoing #preclinical research and development of disease-modifying #therapy for #patients with #Parkinsons
Read more: bit.ly/3ExYqk2
#biotech #research #neuroscience #MJFF #neurodegeneration
Don Nicholson retweeted
Allosteric TYK2. No black box. I told you so. Years ago. businesswire.com/news/home/2…™-deucravacitinib-Oral-Treatment-for-Adults-with-Moderate-to-Severe-Plaque-Psoriasis
Don Nicholson retweeted
Surprising Resilience Of Private VC-Backed Biotech Markets
2022 is off to fastest start for VC financings than every year except '21
Over $6B has been invested in 2Q 2022 far more than 2Q in all but 2020-'21
June 2022 was also huge, 2nd biggest ever
lifescivc.com/2022/07/surpri…
Don Nicholson retweeted
Disc is excited to announce the initiation of our Phase 1b/2 Study of DISC-0947 in #myelofibrosis patients with #anemia, the first of several studies we plan to initiate across our portfolio.
Learn more: discmedicine.com/news/disc-m…
Don Nicholson retweeted
TYK2 is a critical target for #autoimmunedisease, as this post by @JebKeiper explains. We designed an allosteric inhibitor, now in Ph2 studies, to achieve specific inhibition of TYK2 & have been pleased to share Ph1 data at #SID2022 and #AAD2022 this year lifescivc.com/2021/03/select…
Don Nicholson retweeted
Allosteric TYK2 inhibitor deucravacitinib has "successful Ph2 in lupus (SLE) from $BMY. Full data at a scientific conference this year. $4B+ sales in 2029 expected" Today's news underscores importance of the allosteric TYK2 mechanism for inflammatory & autoimmune disease.
Don Nicholson retweeted
Join us in welcoming Doug Pagán to Jnana as our CFO and COO! Doug has over 20 years of experience in finance, investor relations, strategy and capital formation in the biopharma industry.
Read more: jnanatx.com/press-releases/j… #drugdiscovery #chemoproteomics
Don Nicholson retweeted
#Porphyrias are a group of serious, rare genetic disorders that result from altered heme synthesis. In celebration of #PorphyriaAwarenessWeek, we want to help raise awareness and talk about #PorphyriaTogether. Stay tuned! #PAW2022